BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McQuade JL, Ologun GO, Arora R, Wargo JA. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep 2020;22:74. [PMID: 32577835 DOI: 10.1007/s11912-020-00913-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. Fecal microbiota transplantation for immunotherapy-resistant urological tumors: Is it time? An update of the recent literature. Cancer 2021. [PMID: 34494666 DOI: 10.1002/cncr.33893] [Reference Citation Analysis]
2 Mclean AE, Kao SC, Barnes DJ, Wong KK, Scolyer RA, Cooper WA, Kohonen-corish MR. The Emerging Role of the Lung Microbiome and its importance in Non-Small Cell Lung Cancer Diagnosis and Treatment. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.011] [Reference Citation Analysis]
3 Yu ZK, Xie RL, You R, Liu YP, Chen XY, Chen MY, Huang PY. The role of the bacterial microbiome in the treatment of cancer. BMC Cancer 2021;21:934. [PMID: 34412621 DOI: 10.1186/s12885-021-08664-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
5 Lee MH. Harness the functions of gut microbiome in tumorigenesis for cancer treatment. Cancer Commun (Lond) 2021. [PMID: 34355542 DOI: 10.1002/cac2.12200] [Reference Citation Analysis]
6 Tashiro H, Shore SA. The Gut Microbiome and Ozone-induced Airway Hyperresponsiveness. Mechanisms and Therapeutic Prospects. Am J Respir Cell Mol Biol 2021;64:283-91. [PMID: 33091322 DOI: 10.1165/rcmb.2020-0288TR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021;184:5309-37. [PMID: 34624224 DOI: 10.1016/j.cell.2021.09.020] [Reference Citation Analysis]
8 Thomas R, Al-Khadairi G, Decock J. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Front Oncol 2020;10:600573. [PMID: 33718107 DOI: 10.3389/fonc.2020.600573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Gallo M, Adinolfi V, Barucca V, Prinzi N, Renzelli V, Barrea L, Di Giacinto P, Ruggeri RM, Sesti F, Arvat E, Baldelli R, Arvat E, Colao A, Isidori A, Lenzi A, Baldell R, Albertelli M, Attala D, Bianchi A, Di Sarno A, Feola T, Mazziotti G, Nervo A, Pozza C, Puliani G, Razzore P, Ramponi S, Ricciardi S, Rizza L, Rota F, Sbardella E, Zatelli MC; EOLO Group. Expected and paradoxical effects of obesity on cancer treatment response. Rev Endocr Metab Disord 2020. [PMID: 33025385 DOI: 10.1007/s11154-020-09597-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Almonte AA, Rangarajan H, Yip D, Fahrer AM. How does the gut microbiome influence immune checkpoint blockade therapy? Immunol Cell Biol 2021;99:361-72. [PMID: 33147357 DOI: 10.1111/imcb.12423] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Le Poole IC. Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation. Pigment Cell Melanoma Res 2021;34:244-55. [PMID: 33438345 DOI: 10.1111/pcmr.12957] [Reference Citation Analysis]
12 Labadie BW, Balar AV, Luke JJ. Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers (Basel) 2021;13:5415. [PMID: 34771578 DOI: 10.3390/cancers13215415] [Reference Citation Analysis]
13 Amalinei C, Grigoraș A, Lozneanu L, Căruntu I, Giușcă S, Balan RA. The Interplay between Tumour Microenvironment Components in Malignant Melanoma. Medicina 2022;58:365. [DOI: 10.3390/medicina58030365] [Reference Citation Analysis]
14 Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med 2022;28:535-44. [PMID: 35228751 DOI: 10.1038/s41591-022-01695-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chambers LM, Bussies P, Vargas R, Esakov E, Tewari S, Reizes O, Michener C. The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities. Curr Oncol Rep 2021;23:92. [PMID: 34125319 DOI: 10.1007/s11912-021-01079-x] [Reference Citation Analysis]